Quarterly ResultMay 6, 2026, 07:12 AM
Insulet Q1 Revenue $761.7M, Up 33.9%; Raises FY Guidance
AI Summary
Insulet Corporation reported strong first-quarter 2026 financial results, with revenue reaching $761.7 million, a 33.9% increase year-over-year, exceeding its guidance range. Net income significantly improved to $91.1 million, or $1.30 per diluted share. Following this performance, the company raised its full-year 2026 total company revenue guidance to 21-23% constant currency growth and highlighted strategic advancements including the expansion of Omnipod 5 availability and a share repurchase program.
Key Highlights
- Q1 2026 revenue was $761.7 million, up 33.9% (30.1% constant currency) year-over-year.
- Q1 2026 net income was $91.1 million, or $1.30 per diluted share, compared to $0.50 per diluted share in prior year.
- Full Year 2026 total company revenue guidance raised to 21-23% constant currency growth.
- Total Omnipod revenue increased 36.9% to $758.4 million (33.0% constant currency).
- International Omnipod revenue grew 59.4% to $242.9 million (45.2% constant currency).
- Operating income for Q1 2026 was $122.1 million, or 16.0% of revenue, up 40 basis points.
- Company repurchased 1.25 million shares of common stock.
- Launched Omnipod 5 and Omnipod Discover in five new countries in the Middle East.